News & Updates
Filter by Specialty:
Is 5-year interval sufficient for prostate cancer screening in older men?
Diagnosis, progression, or death due to prostate cancer occur at approximately a decade to 15 years following an initial assessment of prostate-specific antigen (PSA) levels in older men, according to a study presented at EAU 2022.
Is 5-year interval sufficient for prostate cancer screening in older men?
18 Aug 2022
Local failure tied to survival in intermediate-risk PCa after definitive radiotherapy
In men with intermediate- or high-risk prostate cancer (PCa), local failure after definitive radiation therapy (RT) is indicative of survival outcomes, according to a recent study.
Local failure tied to survival in intermediate-risk PCa after definitive radiotherapy
18 Aug 2022
Survival benefit with postchemoradiation immunotherapy affirmed
Starting immunotherapy after chemotherapy and radiation for unresectable stage III nonsmall cell lung cancer (NSCLC) prolongs overall survival, regardless of patient age, health, and socioeconomic status, according to a large US study.
Survival benefit with postchemoradiation immunotherapy affirmed
15 Aug 2022
Mammography screening tied to better breast cancer characteristics, outcomes
Regularly attending mammography screening sessions may lead to better breast cancer (BC) characteristics and help improve overall survival (OS), reports a recent Singapore study.
